Arch Therapeutics, Inc, together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures. Read More…

When is Arch Therapeutics' next earnings date?

What price target have analysts set for ARTH?

4 brokerages have issued 12 month price targets for Arch Therapeutics' shares. Their predictions range from $1.25 to $2.50. On average, they expect Arch Therapeutics' share price to reach $1.8750 in the next twelve months. This suggests a possible upside of 600.9% from the stock's current price. View Analyst Price Targets for Arch Therapeutics.

What is the consensus analysts' recommendation for Arch Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arch Therapeutics.

What are Wall Street analysts saying about Arch Therapeutics stock?

Here are some recent quotes from research analysts about Arch Therapeutics stock:

1. According to Zacks Investment Research, "Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company's lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts. " (8/6/2019)

2. LADENBURG THALM/SH SH analysts commented, "We are looking forward to the European agency’s decision, which is expected by this fall. While EU authorities typically render its decision in six months, we believe there is a backlog delaying its decision, driven by recent changes in the governing rules and the impact from Brexit. Arch management has reportedly not heard from the agency and, “…expects the review process to be completed this fall” (10-Q)." (8/5/2019)

Has Arch Therapeutics been receiving favorable news coverage?

Headlines about ARTH stock have trended somewhat positive on Sunday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arch Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Arch Therapeutics.

How do I buy shares of Arch Therapeutics?

Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arch Therapeutics' stock price today?

One share of ARTH stock can currently be purchased for approximately $0.2675.

How can I contact Arch Therapeutics?

MarketBeat Community Rating for Arch Therapeutics (OTCMKTS ARTH)

Community Ranking:

2.4 out of 5 ()

Outperform Votes:

167 (Thanks for Voting!)

Underperform Votes:

179 (Thanks for Voting!)

Total Votes:

346

MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote "Outperform" if you believe ARTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days.